Hesperidin and Bone Health in Postmenopausal Women
| Status: | Completed |
|---|---|
| Conditions: | Osteoporosis, Osteoporosis, Postmenopausal Syndrome |
| Therapuetic Areas: | Endocrinology, Rheumatology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 5/19/2018 |
| Start Date: | April 2011 |
| End Date: | October 2012 |
The primary objective of this clinical trial is to test hesperidin with and without
CALCILOCK® for bone resorption suppressing effect in postmenopausal women. The secondary
objective is the comparison between 41Ca technology and classical biomarker to evaluate bone
resorption.
CALCILOCK® for bone resorption suppressing effect in postmenopausal women. The secondary
objective is the comparison between 41Ca technology and classical biomarker to evaluate bone
resorption.
Subjects will participate in four phases of the study: Baseline of 50 days and three
intervention phases which include 50 days receiving product followed by 50 days of recovery.
The total duration of the study will be 350 days. If participant has not been previously
labeled with 41Ca, a 150 day period is added to the study.
Hesperidin (552mg) and Calcilock® (amount per day: Calcium: 684 mg; Phosphorus: 282mg;
Magnesium: 102mg; Zinc: 2.86mg; Vitamin C: 20 mg; Vitamin K1: 28µg; Vitamin D: 1.86µg) will
be administered in the form of cookies (biscuit).
intervention phases which include 50 days receiving product followed by 50 days of recovery.
The total duration of the study will be 350 days. If participant has not been previously
labeled with 41Ca, a 150 day period is added to the study.
Hesperidin (552mg) and Calcilock® (amount per day: Calcium: 684 mg; Phosphorus: 282mg;
Magnesium: 102mg; Zinc: 2.86mg; Vitamin C: 20 mg; Vitamin K1: 28µg; Vitamin D: 1.86µg) will
be administered in the form of cookies (biscuit).
Inclusion Criteria:
- Women at least 4 years postmenopausal
Exclusion Criteria:
- Medications affecting bone resorption
We found this trial at
1
site
Click here to add this to my saved trials
